Nick Olsen

At Weave Bio, we’re building the backbone for modern drug development. Drug development teams deserve tools that match the pace and complexity of their science. Our AI-native platform supports biotech and pharma organizations at every step, with a focus on regulatory workflows that bring clarity, connection, and efficiency to documentation so therapies can move forward without unnecessary delays. We partner with scientists, clinicians, and regulatory professionals who are advancing the next generation of medicines. By improving the processes behind regulatory documentation, Weave helps reduce bottlenecks and frees teams to focus on what matters most — discovery, innovation, and patient impact. Our approach is human-driven and technology-powered. We believe that combining scientific expertise with AI innovation can transform how life sciences organizations operate, making the development of therapies more efficient, compliant, and collaborative. Weave is a small but mighty team of scientists, engineers, and industry experts united by a shared mission: helping life-changing medicines reach patients faster. Our collective experience across biotechnology, software, and regulation gives us deep insight into the challenges of drug development — and the passion to build solutions that make a lasting impact. We’re proud to work side by side with our partners to move science forward and build the foundation that drug development teams need today and tomorrow.

Innovation Endeavors is an early-stage venture capital firm that invests in cutting-edge technologies to drive generational change in order to solve problems that matter. The firm’s central investment thesis, the Super Evolution, combines data, computational capacity, and advanced engineering to transform a range of industries including engineering health, climate, computing infrastructure, intelligent software, the physical economy, and more. Its investments include Afresh, AlphaSense, Atom Computing, Color, Gatik, Eikon Therapeutics, Fabric, Homelight, Kong, Formlabs, Panther, Planet, Replica, SoFi, Uber, Upstart, Vicarious Surgical, and more.

At Weave Bio, we’re building the backbone for modern drug development. Drug development teams deserve tools that match the pace and complexity of their science. Our AI-native platform supports biotech and pharma organizations at every step, with a focus on regulatory workflows that bring clarity, connection, and efficiency to documentation so therapies can move forward without unnecessary delays. We partner with scientists, clinicians, and regulatory professionals who are advancing the next generation of medicines. By improving the processes behind regulatory documentation, Weave helps reduce bottlenecks and frees teams to focus on what matters most — discovery, innovation, and patient impact. Our approach is human-driven and technology-powered. We believe that combining scientific expertise with AI innovation can transform how life sciences organizations operate, making the development of therapies more efficient, compliant, and collaborative. Weave is a small but mighty team of scientists, engineers, and industry experts united by a shared mission: helping life-changing medicines reach patients faster. Our collective experience across biotechnology, software, and regulation gives us deep insight into the challenges of drug development — and the passion to build solutions that make a lasting impact. We’re proud to work side by side with our partners to move science forward and build the foundation that drug development teams need today and tomorrow.

Bain & Company is a global consultancy that helps the world’s most ambitious change makers define the future. Across 65 cities in 40 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition, and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster, and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise, and insight to organizations tackling today’s urgent challenges in education, racial equity, social justice, economic development, and the environment. We earned a platinum rating from EcoVadis, the leading platform for environmental, social, and ethical performance ratings for global supply chains, putting us in the top 1% of all companies. Since our founding in 1973, we have measured our success by the success of our clients.